Introduction
BrainsWay Ltd. (NASDAQ: BWAY), a pioneer in advanced noninvasive neurostimulation treatments, recently released its financial results for the third quarter of 2025, showcasing substantial revenue growth and significant operational activities. This update is crucial as it highlights the company's ongoing commitment to improving mental health through innovative technology.
Financial Highlights of Q3 2025
Revenue Surge
In the third quarter of 2025, BrainsWay reported a remarkable revenue increase of 29%, amounting to $13.5 million. This surge is compared to the performance of the same quarter in 2024 and reflects the growing demand for the company's neurostimulation solutions.
Operating Income and Adjusted EBITDA Growth
The company's operating income for Q3 2025 totaled $1.3 million, a significant rise compared to the previous year. Furthermore, the Adjusted EBITDA experienced an impressive 80% growth, reaching approximately $2.0 million, reflecting the efficacy of BrainsWay's operational strategies and market positioning.
Remaining Performance Obligations
As of the end of September 2025, BrainsWay reported $65 million in remaining performance obligations. This figure largely stems from multi-year lease agreements, indicating strong customer commitment to the company's products and services.
FDA Protocol Approval
An important milestone was achieved when the U.S. Food and Drug Administration (FDA) cleared an accelerated protocol for the Deep TMS treatment of patients suffering from major depressive disorder (MDD), including those experiencing anxiety symptoms alongside depression. This approval is expected to significantly enhance treatment accessibility for patients.
Operational Updates
Increased System Installations
During Q3 2025, BrainsWay shipped a total of 90 Deep TMS™ systems, marking a 43% increase compared to the same period last year. This brings the total number of installed systems to over 1,600, reinforcing the company's leadership in the neurostimulation market.
Investment in Future Technologies
BrainsWay has also fostered strategic partnerships through minority equity investments, with four new investments announced in 2025. Among these is a $5 million strategic investment in Neurolief Ltd., a company developing wearable brain neuromodulation platforms for home use. This collaboration aims to combine therapeutic approaches for enhanced patient care.
Financial Guidance for Full-Year 2025
Looking ahead, BrainsWay has revised its financial guidance for the full year of 2025. With improved market visibility and continued strong performance trends, it projects revenues between $51 million and $52 million. The expectations for both operating income and Adjusted EBITDA have also been elevated, indicating positive growth trajectories.
Management Commentary
During the announcement of these results, Hadar Levy, CEO of BrainsWay, remarked on the favorable market dynamics supporting the company's growth. He emphasized the potential for new therapeutic indications and the development of accelerated treatment protocols as avenues to strengthen BrainsWay's market footprint further.
Conclusion
BrainsWay Ltd. continues to demonstrate robust growth and innovative advancements in noninvasive neurostimulation treatments. The company's recent financial results provide a promising outlook for future operations and reinforce its commitment to enhancing mental health treatment options globally.
Frequently Asked Questions
What is BrainsWay known for?
BrainsWay is recognized for its advanced noninvasive neurostimulation treatments aimed at addressing mental health disorders.
What was BrainsWay's revenue in Q3 2025?
The company's revenue in Q3 2025 was reported at $13.5 million, marking a 29% increase from the previous year.
What is Deep TMS?
Deep TMS is a proprietary technology developed by BrainsWay for the treatment of conditions like major depressive disorder and anxiety.
How much did BrainsWay’s Adjusted EBITDA grow in Q3 2025?
BrainsWay's Adjusted EBITDA rose approximately 80% to $2.0 million in Q3 2025.
What future developments does BrainsWay anticipate?
BrainsWay expects to explore new therapeutic applications and enhance treatment protocols, alongside fostering collaborations that integrate new technologies into their offerings.
